Who needs to care about small, dense low density lipoproteins?

Manfredi Rizzo, Kaspar Berneis

Risultato della ricerca: Article

40 Citazioni (Scopus)

Abstract

Background: Increasing evidence suggest that the ‘quality’ rather than only the‘quantity’ of low-density lipoprotein (LDL) exerts a great influence on the cardiovascularrisk. Small, dense LDL seem to be an important predictor of cardiovascularevents and progression of coronary artery disease (CAD) and their predominancehas been accepted as an emerging cardiovascular risk factor by the National CholesterolEducation Program Adult Treatment Panel III. Discussion: Some studiesshowed in past years that small, dense LDL are usually elevated in patients at veryhigh cardiovascular risk, such as those with CAD and type 2 diabetes. Morerecently elevated levels of these particles have been found in other categories ofpatients at high cardiovascular risk, such as those with non-coronary forms of atherosclerosis(e.g. with carotid artery disease, aortic abdominal aneurysm andperipheral arterial disease) and metabolic diseases (with polycystic ovary syndromeand growth hormone deficiency); notably, in most of them, the predominance ofsmall, dense LDL characterised their type of dyslipidaemia, alone or in combinationwith elevated triglycerides and reduced high-density lipoproteins cholesterol concentrations.Conclusions: The therapeutical modulation of small, dense LDL havebeen shown to significantly reduce cardiovascular risk and weight reduction andincreased physical activity may constitute first-line therapy. In addition, lipid-loweringdrugs are able to favourably alter these particles and fibrates and nicotinic acidseem to be the most effective agents. Promising data are also available with theuse of rosuvastatin, the latest statin introduced in the market, and ezetimibe, acholesterol absorption inhibitor
Lingua originaleEnglish
pagine (da-a)1949-1956
Numero di pagine8
RivistaInternational Journal of Clinical Practice
Volume61
Stato di pubblicazionePublished - 2007

Fingerprint

LDL Lipoproteins
Coronary Artery Disease
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Carotid Artery Diseases
Metabolic Diseases
Abdominal Aortic Aneurysm
Risk Reduction Behavior
Dyslipidemias
Type 2 Diabetes Mellitus
HDL Cholesterol
Growth Hormone
Weight Loss
Ovary
Atherosclerosis
Triglycerides
Exercise
Lipids
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cita questo

Who needs to care about small, dense low density lipoproteins? / Rizzo, Manfredi; Berneis, Kaspar.

In: International Journal of Clinical Practice, Vol. 61, 2007, pag. 1949-1956.

Risultato della ricerca: Article

@article{c28c3f179900492ab2effdcb6bd00c34,
title = "Who needs to care about small, dense low density lipoproteins?",
abstract = "Background: Increasing evidence suggest that the ‘quality’ rather than only the‘quantity’ of low-density lipoprotein (LDL) exerts a great influence on the cardiovascularrisk. Small, dense LDL seem to be an important predictor of cardiovascularevents and progression of coronary artery disease (CAD) and their predominancehas been accepted as an emerging cardiovascular risk factor by the National CholesterolEducation Program Adult Treatment Panel III. Discussion: Some studiesshowed in past years that small, dense LDL are usually elevated in patients at veryhigh cardiovascular risk, such as those with CAD and type 2 diabetes. Morerecently elevated levels of these particles have been found in other categories ofpatients at high cardiovascular risk, such as those with non-coronary forms of atherosclerosis(e.g. with carotid artery disease, aortic abdominal aneurysm andperipheral arterial disease) and metabolic diseases (with polycystic ovary syndromeand growth hormone deficiency); notably, in most of them, the predominance ofsmall, dense LDL characterised their type of dyslipidaemia, alone or in combinationwith elevated triglycerides and reduced high-density lipoproteins cholesterol concentrations.Conclusions: The therapeutical modulation of small, dense LDL havebeen shown to significantly reduce cardiovascular risk and weight reduction andincreased physical activity may constitute first-line therapy. In addition, lipid-loweringdrugs are able to favourably alter these particles and fibrates and nicotinic acidseem to be the most effective agents. Promising data are also available with theuse of rosuvastatin, the latest statin introduced in the market, and ezetimibe, acholesterol absorption inhibitor",
author = "Manfredi Rizzo and Kaspar Berneis",
year = "2007",
language = "English",
volume = "61",
pages = "1949--1956",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Who needs to care about small, dense low density lipoproteins?

AU - Rizzo, Manfredi

AU - Berneis, Kaspar

PY - 2007

Y1 - 2007

N2 - Background: Increasing evidence suggest that the ‘quality’ rather than only the‘quantity’ of low-density lipoprotein (LDL) exerts a great influence on the cardiovascularrisk. Small, dense LDL seem to be an important predictor of cardiovascularevents and progression of coronary artery disease (CAD) and their predominancehas been accepted as an emerging cardiovascular risk factor by the National CholesterolEducation Program Adult Treatment Panel III. Discussion: Some studiesshowed in past years that small, dense LDL are usually elevated in patients at veryhigh cardiovascular risk, such as those with CAD and type 2 diabetes. Morerecently elevated levels of these particles have been found in other categories ofpatients at high cardiovascular risk, such as those with non-coronary forms of atherosclerosis(e.g. with carotid artery disease, aortic abdominal aneurysm andperipheral arterial disease) and metabolic diseases (with polycystic ovary syndromeand growth hormone deficiency); notably, in most of them, the predominance ofsmall, dense LDL characterised their type of dyslipidaemia, alone or in combinationwith elevated triglycerides and reduced high-density lipoproteins cholesterol concentrations.Conclusions: The therapeutical modulation of small, dense LDL havebeen shown to significantly reduce cardiovascular risk and weight reduction andincreased physical activity may constitute first-line therapy. In addition, lipid-loweringdrugs are able to favourably alter these particles and fibrates and nicotinic acidseem to be the most effective agents. Promising data are also available with theuse of rosuvastatin, the latest statin introduced in the market, and ezetimibe, acholesterol absorption inhibitor

AB - Background: Increasing evidence suggest that the ‘quality’ rather than only the‘quantity’ of low-density lipoprotein (LDL) exerts a great influence on the cardiovascularrisk. Small, dense LDL seem to be an important predictor of cardiovascularevents and progression of coronary artery disease (CAD) and their predominancehas been accepted as an emerging cardiovascular risk factor by the National CholesterolEducation Program Adult Treatment Panel III. Discussion: Some studiesshowed in past years that small, dense LDL are usually elevated in patients at veryhigh cardiovascular risk, such as those with CAD and type 2 diabetes. Morerecently elevated levels of these particles have been found in other categories ofpatients at high cardiovascular risk, such as those with non-coronary forms of atherosclerosis(e.g. with carotid artery disease, aortic abdominal aneurysm andperipheral arterial disease) and metabolic diseases (with polycystic ovary syndromeand growth hormone deficiency); notably, in most of them, the predominance ofsmall, dense LDL characterised their type of dyslipidaemia, alone or in combinationwith elevated triglycerides and reduced high-density lipoproteins cholesterol concentrations.Conclusions: The therapeutical modulation of small, dense LDL havebeen shown to significantly reduce cardiovascular risk and weight reduction andincreased physical activity may constitute first-line therapy. In addition, lipid-loweringdrugs are able to favourably alter these particles and fibrates and nicotinic acidseem to be the most effective agents. Promising data are also available with theuse of rosuvastatin, the latest statin introduced in the market, and ezetimibe, acholesterol absorption inhibitor

UR - http://hdl.handle.net/10447/2472

M3 - Article

VL - 61

SP - 1949

EP - 1956

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

ER -